Company profilePharmaceutical#141 of 1,318 in Pakistan✓ No DRAP alerts

De-Mont Research Laboratories (Pvt.) Ltd.

Pharmaceutical company · 118 brands · 99 molecules

Ranked #17 of 51 companies in Antimycotics Systemic Use

118 registered products 39 pharmaceutical brands 99 distinct molecules 0 DRAP alerts

Company overview

118
registered products
39
pharmaceutical brands
99
distinct molecules
2
therapeutic classes
0
DRAP alerts

De-Mont Research Laboratories (Pvt.) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 118 product registrations across 99 distinct molecules. It is the 141st largest registrant in Pakistan by product count, and ranks 17th of 51 in Antimycotics Systemic Use. Its portfolio is concentrated in Antimycotics Systemic Use and Other Vitamins. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by De-Mont

90 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Macrolides, Lincosamides And Streptogramins 2
Other Beta-Lactam, Cephalosporins & Penems 2
Antimycotics Systemic Use 1
Antivirals For Systemic Use 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

90
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202590

Top molecules by brand count

Therapeutic classes

Antimycotics Systemic Use · 1Other Vitamins · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official145 products · Rs 81.23 – Rs 7,615.05
Median across source: Rs 431.52

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 166 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAgomelatine
Winlet Pharmaceuticals (Pvt) Ltd. holds 33 molecules not in this portfolio
000 I.UCholecalciferolClomifeneClomiphineClopidogrelElemental Iron
GETZ PHARMA PAKISTAN (PVT) LTD. holds 245 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAdrenalineAlbendazoleAmitriptyline

Get the full profile for De-Mont

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.